Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ).
Nanjing Leads Biolabs Co., Ltd. announced the presentation of clinical data for its drug candidate LBL-034 at the 67th ASH Annual Meeting. The study, conducted across 17 centers in China, showed promising results in treating relapsed/refractory multiple myeloma, with high objective response rates and manageable side effects. The drug’s strong efficacy and safety profile highlight its potential as a best-in-class therapy, reinforcing the company’s position in the global biopharmaceutical market.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a biotechnology company based in China, specializing in the development of innovative drug candidates, particularly in the field of hematology. The company focuses on creating bispecific antibodies for the treatment of relapsed or refractory multiple myeloma, utilizing its proprietary LeadsBody® platform.
Average Trading Volume: 679,191
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.28B
See more insights into 9887 stock on TipRanks’ Stock Analysis page.